{"id":10923,"date":"2026-10-21T05:22:05","date_gmt":"2026-10-21T09:22:05","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=10923"},"modified":"2026-10-21T05:23:26","modified_gmt":"2026-10-21T09:23:26","slug":"medicure-will-be-30-within-12-months","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/medicure-will-be-30-within-12-months\/","title":{"rendered":"Medicure Gains Another 2.33% to $4.40 and Will Be $30+ Within 12 Months"},"content":{"rendered":"\n
\n

Medicure (TSXV: MPH) gained another 2.33%<\/span><\/strong> yesterday to $4.40 per share<\/strong> and has the #1 most bullish<\/span> chart<\/strong> on the TSX Venture Exchange. MPH<\/strong> is the world's<\/span> #1 lowest<\/span> market cap biotech stock<\/strong> that has an FDA Rare Pediatric Disease Designation<\/strong>, Orphan Drug Designation<\/strong>, Fast Track Designation<\/strong>, and fully enrolled<\/span> Phase 3 trials<\/strong> taking place<\/strong><\/span> right now. Because PNPO deficiency<\/strong><\/span> is a very rare genetic neurometabolic disorder<\/strong><\/span> that causes severe drug-resistant epileptic seizures<\/strong><\/span> in children<\/strong> within the first<\/span> two weeks of life<\/strong>, there isn't<\/strong><\/span> enough "profit<\/span>"<\/strong> for the evil<\/span> large-cap big pharma companies<\/strong> to develop<\/span> drugs<\/strong> for it. To incentivize<\/span> MPH<\/strong> to develop<\/span> MC-1<\/strong> and save<\/strong><\/span> the children suffering<\/span><\/strong> from PNPO deficiency<\/strong><\/span>, MPH<\/strong> will be receiving<\/strong><\/span> an FDA Priority Review Voucher<\/strong><\/span> after it receives<\/span> FDA approval<\/strong>. These vouchers<\/strong> are worth US$203-$210 million<\/strong><\/span> based on recent transactions so when we say MPH<\/strong> will be $30+ per share<\/strong> within the next twelve months we consider it to be a 100% fact<\/strong><\/span>.<\/p>\n\n

Yes, we were inspired<\/strong><\/span> to invest<\/strong><\/span> in MPH<\/strong> by seeing Peter Thiel<\/strong> and Christian Angermayer<\/strong> profit billions of dollars<\/strong><\/span> on AtaiBeckley<\/strong>, but they have nothing<\/strong><\/span> to do with MPH<\/strong> this is NIA's discovery<\/span><\/strong>.<\/p>\n\n

Their Apeiron Investment Group<\/strong> is investing<\/strong><\/span> into Super Copper (CSE: CUPR)<\/strong> to solve<\/strong><\/span> the upcoming copper<\/span> supply deficit<\/span><\/strong> being created by rapidly rising demand<\/strong><\/span> for AI<\/strong> and the power infrastructure<\/strong> that must be built<\/strong><\/span> over the next few years to bring<\/strong><\/span> AI data centers<\/strong> online<\/strong><\/span>. They are much smarter<\/strong><\/span> than us, so we suggest fully focusing your research<\/strong><\/span> on Super Copper<\/strong>.<\/p>\n\n

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA's President has purchased 87,000 shares of MPH and intends to buy more shares. NIA has received US$50,000 cash from CUPR for a six-month marketing contract and previously received US$30,000 cash for a three-month marketing contract and CUPR has agreed to extend the contract for an additional three months for US$30,000 cash. This communication is for informational and educational purposes only.<\/em><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Medicure (TSXV: MPH) gained another 2.33% yesterday to $4.40 per share and has the #1 most bullish chart on the TSX Venture Exchange. MPH is the world's #1 lowest market cap biotech stock that has an FDA Rare Pediatric Disease Designation, Orphan Drug Designation, Fast Track Designation, and fully enrolled Phase 3 trials taking place […]<\/p>\n","protected":false},"author":1,"featured_media":10924,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,48,230,414,8],"class_list":["post-10923","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-copper","tag-cupr","tag-mph","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/10923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=10923"}],"version-history":[{"count":2,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/10923\/revisions"}],"predecessor-version":[{"id":10926,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/10923\/revisions\/10926"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/10924"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=10923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=10923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=10923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}